Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era  by Hohnloser, Stefan H et al.
Prevalence, Characteristics and Prognostic
Value During Long-Term Follow-up of
Nonsustained Ventricular Tachycardia After
Myocardial Infarction in the Thrombolytic Era
Stefan H. Hohnloser, MD, FACC, Thomas Klingenheben, MD, Markus Zabel, MD,
Matthias Scho¨pperl, MD, Oliver Mauß, MSC
Frankfurt, Germany
OBJECTIVES The purpose of this study was to determine the prevalence, characteristics and the predictive
value of nonsustained ventricular tachycardia (VT) for subsequent death and arrhythmic
events after acute myocardial infarction (AMI).
BACKGROUND Nonsustained VT has been linked to an increased risk for sudden death in coronary patients.
It is unknown whether this parameter can be used for selection of high-risk patients to receive
an implantable defibrillator for primary prevention of sudden death in patients shortly after
AMI.
METHODS In 325 consecutive infarct survivors, 24-h Holter monitoring was performed 10 6 6 days after
AMI. All patients underwent coronary angiography, determination of left ventricular
function and assessment of heart rate variability (HRV). Mean follow-up was 30 6 22
months.
RESULTS There was a low prevalence (9%) of nonsustained VT shortly after AMI. Nonsustained VT
together with depressed left ventricular ejection fraction (LVEF) was found in only 2.4% of
patients. During follow-up, 25 patients reached one of the prospectively defined end points
(primary composite end point of cardiac death, sustained VT or resuscitated ventricular
fibrillation; secondary end point: arrhythmic events). Kaplan Meier event probability analyses
revealed that only HRV, LVEF and status of the infarct-related artery were univariate
predictors of death or arrhythmic events. The presence of nonsustained VT carried a relative
risk of 2.6 for the primary study end point but was not a significant predictor if only
arrhythmic events were considered. On multivariate analysis, only HRV, LVEF and the
status of the infarct artery were found to be independently related to the primary study end
point.
CONCLUSIONS There is a low prevalence of nonsustained VT shortly after AMI. Only 2% to 3% of all infarct
survivors treated according to contemporary guidelines demonstrate both depressed LVEF
and nonsustained VT. The predictive value of nonsustained VT for subsequent mortality and
arrhythmic events is inferior to that of impaired autonomic tone, LVEF or infarct-related
artery patency. Accordingly, the use of nonsustained VT to select patients for primary
implantable cardioverter/defibrillator prevention trials shortly after AMI appears to be
limited. (J Am Coll Cardiol 1999;33:1895–902) © 1999 by the American College of
Cardiology
In studies conducted before the widespread use of acute
revascularization therapy in acute myocardial infarction
(AMI), the presence of nonsustained ventricular tachycardia
(VT) was found to be a marker of increased risk for
subsequent all-cause and arrhythmic mortality (1–3). In the
thrombolytic era, the prognostic significance of nonsus-
tained VT is more controversial (4,5). For instance, the
GISSI-2 investigators found nonsustained VT in only 6.8%
of infarct survivors undergoing thrombolytic therapy, and its
presence was not an independent predictor of subsequent
all-cause or arrhythmic mortality (4). Preliminary data from
more recent studies indicate an even lower incidence of
nonsustained VT after AMI, even in the presence of
depressed left ventricular function (6). On the other hand,
the MADIT trial, so far the only primary prevention study
demonstrating superiority of cardioverter/defibrillator im-
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plantation compared with conventional antiarrhythmic
treatment in coronary patients, used Holter-documented
asymptomatic nonsustained VT together with reduced left
ventricular function as its primary selection criteria (7).
However, because .75% of patients enrolled had had their
infarct more than six months before study entry (7), it
remains to be demonstrated whether the presence of non-
sustained VT serves as a prognostic marker shortly after
AMI.
Accordingly, the present study examined the incidence,
the characteristics and the predictive value of nonsustained
VT for cardiac death and arrhythmic events in a large
sample of consecutive infarct survivors treated at a single
institution according to contemporary therapeutic guide-
lines. The value of nonsustained VT as a predictor of
subsequent risk was compared with that of other established
risk stratifiers such as left ventricular function, patency of
the infarct-related artery or markers of autonomic tone.
Patients were prospectively followed for 30 6 22 months.
METHODS
Patient population. Consecutive patients presenting with
AMI were considered for entry in the present study.
Patients were eligible for participation if the following
inclusion criteria were met: 1) a confirmed diagnosis of
AMI based on clinical presentation (typical chest pain for
.30 min, unresponsive to nitrates; ST segment elevation in
at least two limb leads of .0.1 mV or in at least two
precordial leads of $0.2 mV; elevated CK and CKMB
levels), 2) Holter monitoring was performed before hospital
discharge. All patients gave informed consent before entry
in the study.
Follow-up. After discharge, patients were seen in the
arrhythmia outpatient clinic at 4, 8 and 12 months after
AMI, and in 6-month intervals thereafter. All episodes of
nonfatal arrhythmic events, reinfarction and revasculariza-
tion procedures were carefully recorded. Information about
deceased patients was obtained from family members, their
general practitioners and from the hospitals to which they
had been admitted. Particular attention was given to the
circumstances of each death.
The primary end point of the study was prospectively
defined as a composite end point of cardiac mortality,
documented sustained VT and resuscitated ventricular fi-
brillation (VF). A secondary end point of the study was
arrhythmic events (defined as sudden cardiac death, docu-
mented sustained VT and resuscitated VF). Sudden death
was defined as instantaneous, unexpected death or death
within 1 h of symptoms onset not related to circulatory
failure. Sustained VT was defined as a documented tachy-
cardia of ventricular origin at a rate of $100 bpm and
lasting for .30 s or resulting in hemodynamic collapse.
Coronary angiography. Selective coronary angiography
was performed by the Judkins technique in all patients 7 to
30 days after the infarct. Multiple orthogonal views were
obtained and recorded at standardized angles on cineangio-
graphic film. After catheterization, the cineangiograms were
reviewed independently and without knowledge of other
clinical parameters. Antegrade perfusion of the infarct artery
was graded according to the classification system of the
Thrombolysis in Myocardial Infarction (TIMI) trial (8).
Patients with an initially occluded artery who were revas-
cularized before hospital discharge were considered to have
a patent vessel during the statistical analysis.
Holter monitoring. Before hospital discharge (10 6 6 days
after AMI) and in stable clinical conditions, patients un-
derwent 24-h ambulatory monitoring (modified V2 and V5
leads) using two-channel bipolar Holter recorders (model
8500; Marquette, Milwaukee, Wisconsin). The tapes were
subsequently analyzed by running a laser scanner (model
8000, Marquette) with its arrhythmia analysis program to
identify and label each QRS complex.
The presence of nonsustained VT was defined according
to criteria previously defined in a prospective trial evaluating
the value of prophylactic implantation of a cardioverter/
defibrillator in survivors of myocardial infarction (7). Ac-
cordingly, at least three consecutive premature ventricular
beats at a rate of $120 beats/min were considered nonsus-
tained VT. All respective episodes were printed out from
the Holter recordings and verified by a single experienced
investigator who was blinded as to the clinical information
of the patient. Analysis of heart rate variability (HRV) was
performed as previously reported (9,10). The reproducibility
of HRV determination in our laboratory has been published
previously (9). A prospectively defined cut-point of the
HRV index standard deviation of normal-to-normal inter-
vals (SDNN) #70 ms was used to define a high-risk group
(11).
Determination of left ventricular function. Left ventric-
ular ejection fraction (LVEF) was calculated from the 30°
right anterior oblique ventriculogram using a standard
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CAST 5 cardiac arrythmia suppression trial
CK 5 creatine kinase
HRV 5 heart rate variability
ICD 5 implantable cardioverter/defibrillator
LVEF 5 left ventricular ejection fraction
MADIT 5 multicenter automatic defibrillator
implantation trial
PTCA 5 percutaneous transluminal coronary
angioplasty
SDNN 5 standard deviation of normal-to-normal
intervals
TIMI 5 thrombolysis in myocardial infarction
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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area-length method or by echocardiography or by radionu-
clide ventriculography. All LVEF determinations were done
in duplicate by two separate investigators blinded to the
clinical data of the patient.
Statistical methods. Continuous values are reported as
mean 6 standard deviation. All data were analyzed using
the Statistical Package for the Social Sciences (12). Com-
parisons between patients with and without events during
follow-up were performed by means of the unpaired Stu-
dent t test for normally distributed continuous variables
(two-sided) or the chi-square test for categorical data. The
independent correlation of various risk stratifiers to events
during follow-up was determined by means of logistic
regression analysis with the occurrence of events as the
dependent variable. Sensitivity was defined as the percent of
patients with a positive test result from all patients with an
end point, specificity as the percent of patients with a
negative test result from all patients without an end point
and positive predictive value as the percent of patients with
an end point from all patients with a positive test result.
Kaplan Meier event probability curves (13) were computed,
stratifying patient groups according to the presence or
absence of prespecified risk markers. The cumulative prob-
ability of events of two patient groups was compared by
means of a log-rank test. Significance was considered with a
p value #0.05.
RESULTS
Patient characteristics. From a total of 361 consecutive
patients surviving AMI, Holter recordings at the time of
hospital discharge were obtained in 325 (90%). In 36
patients, long-term electrocardiographic recordings were
not available because patients refused to undergo Holter
monitoring (n 5 11), patients were discharged before
Holter monitoring (n 5 14), or due to technical failures
(n 5 11). Thus, the present analysis is based on data of 325
patients with complete clinical and electrocardiographic
data (Table 1). There were 257 men and 68 women with a
mean age of 58 6 11 years. LVEF averaged 49 6 11%; 51
patients (16%) had a LVEF of #35%. Coronary angiogra-
phy before discharge demonstrated an open infarct-related
artery in 255 of 325 patients (78%). In the remaining 70
patients (22%), the infarct vessel was occluded. Patients
were followed for a mean of 30 6 22 months after the index
infarct (median 25 months). The percentage of patients
treated with beta-adrenergic blocking agents was 80% at
hospital discharge, 67% at one year and 59% at the two-year
follow-up; the respective numbers for aspirin treatment
were 92%, 85% and 80%; and for ACE inhibitors, 41%,
40%, and 38%. During follow-up, antiarrhythmic drug
therapy was instituted in 20 patients for atrial fibrillation or
flutter (n 5 15), or symptomatic ventricular premature beats
(n 5 5). There was only one cardiac death in a patient on
antiarrhythmic drug therapy with sotalol.
Incidence of nonsustained VT after myocardial infarc-
tion. In 29 of 325 patients (9%), Holter monitoring re-
vealed the presence of at least one episode of nonsustained
VT. Eight of these patients (28%) had a LVEF of #35%.
There were no significant differences in clinical character-
istics between patients with or without nonsustained VT.
Characteristics of nonsustained VT after myocardial
infarction. There was an average of 2.2 6 2.4 episodes of
nonsustained VT per patient (range 1–11). Episodes of
nonsustained VT consisted of a mean of 6.0 6 6.1 consec-
utive beats (range 3–34). There was only one patient with a
VT episode of .20 beats; disregarding this episode, the
average VT episode consisted of only 5.0 6 2.9 beats.
Figure 1 shows the distribution of maximal VT length in
all 29 patients. The average cycle length of nonsustained VT
Figure 1. Distribution of maximal length of nonsustained VT
episodes.
Table 1. Patient Characteristics
Patients 325
Gender:
Female 68 (21%)
Male 257 (79%)
Age (yr) 58 6 11 (range 22–79)
Myocardial infarction
Inferior 174 (54%)
Anterior 151 (46%)
Left ventricular ejection fraction 49 6 11% (range 20–77)
Acute revascularization
thrombolysis/PTCA
194 (60%)
Infarct-related artery
Open 255 (78%)
Occluded 70 (22%)
Medication at hospital discharge
Digoxin 26 (8%)
ACE inhibitors 132 (41%)
Beta-blocker 259 (80%)
Aspirin 300 (92%)
Antiarrhythmic drugs 0
PTCA 5 percutaneous transluminal coronary angioplasty.
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episodes was 415 6 65 ms, corresponding to a rate of
145 beats/min. The average number of VT episodes, their
average number of beats and cycle length were similar in
patients with a LVEF #35% compared with VT-positive
patients with preserved left ventricular function (Table 2).
The prevalence of nonsustained VT was similar in patients
with an occluded (6 of 70) compared with those with a
patent (23 of 255; p 5 NS) infarct-related artery.
Events during follow-up. During follow-up, 15 patients
died from cardiac death, which was classified as sudden
cardiac death in 7 patients. Eight additional patients
developed sustained monomorphic VT, and two patients
were successfully resuscitated from documented VF.
Thus, a total of 25 prospectively defined study end points
were observed.
Prognostic value of clinical parameters. Clinical param-
eters including gender, age, infarct location, peak creatine
kinase (CK) levels, thrombolysis or acute percutaneous
transluminal coronary angioplasty (PTCA) and discharge
medication were included in the statistical analysis. On
univariate analysis, event-free survivors were significantly
younger (57 6 11 years) compared with patients dying or
suffering arrhythmic events (64 6 6 years; p 5 0.007).
Thrombolytic therapy or acute rescue PTCA was adminis-
tered less frequently to patients with events during
follow-up (10 of 25 patients, 40%) as compared with
patients without events (184 of 300, 61%; p 5 0.04).
Prognostic value of investigational procedures. Table 3
summarizes the prognostic information derived from the
various investigational tests performed. Five variables were
found to yield prognostic information; depressed left ven-
tricular function and impaired HRV were associated with
the highest positive predictive accuracy and carried the
highest relative risk for reaching the primary study end
Table 2. Characteristics of Nonsustained VT
VT Features All Patients
Patients With
LVEF <35%
Patients With
LVEF >35%
VT episodes 2.2 6 2.4 3.1 6 3.4 1.9 6 2.0
Beats/VT episode 5.0 6 2.9 5.9 6 4.6 4.7 6 1.9
VT cycle length (ms) 415 6 65 399 6 61 422 6 66
LVEF 5 left ventricular ejection fraction; VT 5 ventricular tachycardia.
Table 3. Predictive Value of Various Risk Stratifiers
Risk stratifier
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Relative Risk
(95% CI) p Value
Primary study end point
LVEF #35% 48 87 24 95 5.0 (2.5–9.8) 0.00001
SDNN #70 ms 60 82 22 96 5.5 (2.8–10.8) 0.00001
Occluded IRA 48 81 17 95 3.4 (1.7–6.8) 0.0008
nsVT present 20 92 17 93 2.6 (1.0–6.3) 0.043
PTCA/thrombolysis 40 39 5 89 0.5 (0.9–0.2) 0.04
$10 VPB/h 16 85 8 92 1.1 (0.4–3.1) 0.86
Inferior MI 48 46 7 91 0.8 (1.7–0.4) 0.56
Gender 76 21 7 91 0.8 (2.0–0.3) 0.69
No beta-blocker 28 80 11 93 1.5 (0.7–3.5) 0.32
Diabetes 32 81 12 94 1.9 (0.8–4.2) 0.12
Previous MI 20 82 9 93 1.2 (0.4–3.0) 0.77
Secondary study end point (arrhythmic events)
SDNN #70 ms 53 80 13 97 4.1 (1.7–9.6) 0.0012
Occluded IRA 53 80 13 97 4.1 (1.7–9.6) 0.0012
LVEF #35% 41 86 14 96 3.8 (1.5–9.0) 0.003
nsVT present 12 91 7 95 1.4 (0.3–5.7) 0.67
PTCA/thrombolysis 47 40 4 93 0.6 (1.5–0.2) 0.28
$10 VPB/h 6 85 2 94 0.4 (0.1–2.4) 0.29
Inferior MI 47 46 5 94 0.8 (1.9–0.3) 0.58
Gender 76 21 5 94 0.9 (2.6–0.3) 0.79
No beta-blocker 24 80 6 95 1.2 (0.4–3.6) 0.73
Diabetes 18 80 5 95 0.9 (2.9–0.2) 0.80
Previous MI 12 82 3 94 0.6 (2.6–0.1) 0.50
IRA 5 infarct-related artery; left ventricular ejection fraction; MI, myocardial infarction; nsVT 5 nonsustained VT; PTCA, percutaneous transluminal coronary angioplasty;
SDNN, standard deviation of normal-to-normal intervals; VPB 5 ventricular premature beat.
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point. The corresponding Kaplan Meier curves for survival
free of the primary study end point (composite of cardiac
mortality, documented sustained VT, resuscitated VF) are
shown in Figures 2 through 5.
The same analysis was repeated for the prospectively
defined secondary study end point, i.e., arrhythmic events.
As demonstrated in Table 3, only depressed HRV, a
permanently occluded infarct vessel and reduced LVEF
remained significant predictors of arrhythmic events during
follow-up. The presence of nonsustained VT yielded a
relative risk of only 1.4 for subsequent arrhythmic events,
which did not reach statistical significance (Fig. 5).
Multivariate analysis of risk stratifiers. A stepwise regres-
sion analysis incorporating clinical and investigational vari-
ables was performed to assess independent risk parameters.
For the primary study end point, only SDNN (x2 9.5; p 5
0.002), LVEF (x2 5.0; p 5 0.026) and the status of the
infarct-related artery (x2 4.8; p 5 0.029) were demonstrated
to be independently correlated to outcome. With respect to
the secondary study end point, only SDNN (x2 6.9; p 5
0.009) and the status of the infarct-related artery (x2 5.2;
p 5 0.02) were independent predictors.
DISCUSSION
Main study findings. This large prospective long-term
follow-up study reveals several important findings. There is
a low (9%) incidence of Holter-documented nonsustained
VT in postinfarction patients treated according to contem-
porary therapeutic guidelines, including a high frequency of
revascularization. In only 2.4% of all infarct survivors,
nonsustained VT is found in the presence of reduced left
ventricular function. The average nonsustained VT episode
comprises only five to six beats at a rate of around
145 beats/min. Most important, however, the predictive
value of nonsustained VT for subsequent mortality is low.
Actually, when only arrhythmic events are considered, the
presence of nonsustained VT yields no prognostic value at
all. Evidence of impaired cardiac autonomic tone, a patent
infarct artery and reduced left ventricular function are more
powerful risk predictors.
Prevalence and characteristics of nonsustained VT after
myocardial infarction. Several studies conducted before
the widespread use of acute revascularization therapy for
AMI have attempted to determine the prevalence and the
Figure 2. Kaplan-Meier event probabilities for patients with a
LVEF above and below 35%, considering the composite primary
study end point.
Figure 3. Kaplan-Meier event probabilities for patients with a
patent, compared with those with an occluded infarct-related,
artery considering the composite primary study end point.
Figure 4. Top, Kaplan-Meier event probabilities for patients with
a depressed, compared with those with preserved, HRV consider-
ing the composite primary study end point. Bottom, Kaplan-
Meier event probabilities for patients with a depressed, compared
with those with preserved, HRV considering the secondary study
end point.
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prognostic value of nonsustained VT (2,3,14,15). In these
trials, the prevalence for this arrhythmia ranged between
12% (2) and as high as 21% (15). In most of these studies,
the presence of spontaneous nonsustained VT was found to
be a predictor of all-cause mortality in the first two years
after the index infarction. There is a relative paucity of data
regarding the prevalence of nonsustained VT in infarct
survivors who are treated according to contemporary ther-
apeutic guidelines. One of the largest studies stems from the
Gruppoltaliano per lo Studio della Sopravivenza nell’ In-
farto Miocardito (GISSI) investigators, who reported a low
incidence of nonsustained VT (4). They performed Holter
monitoring at the time of hospital discharge in 8,676 infarct
survivors and found at least one run of nonsustained VT in
only 6.8% of their patients (4), a figure that is very similar to
the one reported in this study. The GISSI investigators
concluded from their observations that the prevalence of
nonsustained VT was much lower than the results of studies
conducted in the prethrombolytic era, whereas the incidence
of ventricular premature beats was comparable with earlier
observations (4).
Only a few studies have described the characteristics of
nonsustained VT detected early after AMI. Bigger et al.
examined 820 infarct survivors and found that in the 12%
of patients with nonsustained VT on Holter monitoring,
26 patients had a three-beat run as their longest episode (2).
Nonsustained VT consisted of 4 to 10 beats in another
61% of individuals, whereas only 11% of patients demon-
strated .10 beats (2). The average VT rate was 121 6
34 beats/min. These findings are comparable with those
reported here, where the average VT rate was around
145 beats/min. Most VT episodes consisted of a 3-beat run,
with only 2 patients having episodes of .10 beats. These
findings are similar to those reported by Denes et al., who
analyzed the Holter recordings of patients enrolled in the
Cardiac Arrhythmia Suppression Trial (CAST) (16). In
that study, VT length averaged 4.8 6 2.4 beats and most
patients had VT runs at rates of 120 to 149 beats/min.
Nonsustained VT in patients with depressed left ventric-
ular function. In the Multicenter Automatic Defibrillator
Inplantation Trial (MADIT) study, the combination of
nonsustained Holter-documented VT and a LVEF #35%
was shown to be effective in screening coronary patients at
high risk for arrhythmogenic death who subsequently ben-
efited from prophylactic implantable cardioverter/
defibrillator (ICD) implantation (7). Accordingly, another
goal of the present study was to determine the prevalence of
this combined selection criterion in patients shortly after
AMI. As expected, the average left ventricular function was
well preserved in our patient population due to strict
adherence to modern concepts of infarct therapy. Only 51 of
325 patients (16%) had a significantly impaired left ventric-
ular function, defined as a LVEF #35%. Nonsustained VT
was present in only 8 of 51 patients, resulting in a prevalence
of the combined risk stratifiers of only 2.4%. This number is
in excellent concordance with a preliminary report compris-
ing 1,625 infarct survivors (6). Depressed LVEF and
nonsustained VT were found in only 3.2% of these patients
(6). These numbers indicate that the selection criteria
defined by the MADIT investigators (7) are prevalent in
only a few patients in the immediate postinfarction period.
Prognostic implication of nonsustained VT. Nonsus-
tained VT was considered to represent a clinically useful risk
stratifier in patients surviving AMI in the prethrombolytic
era (2,3,14). The results of the present study demonstrate
that this seems to no longer be the case. Actually, nonsus-
tained VT was inferior to measures of contractile function
and of impaired autonomic tone. Moreover, when only
arrhythmic events during the follow-up period were taken
into consideration, nonsustained VT was no longer a
statistically significant risk predictor. This is again in accor-
dance with previous reports such as the GISSI-2 findings
(4). In this study, nonsustained VT failed to be a statistically
significant risk predictor, whereas frequent premature beats
were confirmed as independent risk factors for total and
sudden death during the first six months after the acute
event (4). This finding may also indicate that the prognostic
value of nonsustained VT is linked to other variables.
Another recently published study in 471 infarct survivors
Figure 5. Top, Kaplan-Meier event probabilities for patients with,
compared with those without, nonsustained VT considering the
composite primary study end point. Bottom, Kaplan-Meier event
probabilities for patients with, compared with those without,
nonsustained; VT considering the secondary study end point. Note
that there is no predictive value of nonsustained VT concerning
sudden death or arrhythmic events.
1900 Hohnloser et al. JACC Vol. 33, No. 7, 1999
Nonsustained VT After Myocardial Infarction June 1999:1895–902
failed to demonstrate prognostic value of both isolated
premature ventricular beats and nonsustained VT concern-
ing overall mortality after AMI (17).
Postinfarction risk stratification for all-cause mortality
and for arrhythmogenic mortality in particular remains
imperfect. The most likely reason for this is the low overall
postinfarction mortality rate. The bulk of evidence, how-
ever, indicates that probably the most accurate way of
approaching this problem is to take into account measures
of left ventricular function and cardiac autonomic tone.
Several studies utilizing heart rate variability have indicated
this (18–22), and the present study confirms those findings.
A recent large multicenter trial enrolling 1,284 infarct
survivors treated according to modern therapeutic guidelines
is of particular interest (23). In that study, two measures of
cardiac autonomic tone were utilized, namely heart rate
variability and baroreflex sensitivity (9,24,25). The study
provided sound evidence that after myocardial infarction the
analysis of vagal reflexes has significant prognostic value
independently of left ventricular contractile function (23).
As a matter of fact, the highest risk of cardiac death in that
study was found for patients with both a reduction in LVEF
and in autonomic tone, a finding that is in agreement with
the results presented here.
Study limitations. A potential limitation of our study
relates to the sample size: although data of 325 patients were
analyzed, it is still conceivable that an even larger study
would have yielded improved predictive accuracy of nonsus-
tained VT. Another important issue relates to the compar-
ison of the present results with previous findings. For
instance, in the GISSI trial (4), nonsustained VT failed to
be an independent predictor on multivariate analysis, but
ventricular premature beats were predictive. It is possible
that if multivariate analysis would have been performed
omitting the variable ventricular premature beats, nonsus-
tained VT would have become a significant predictor. A
third problem relates to the timing of Holter monitoring
after AMI. In a recent study, 112 patients who had
nonsustained VT within 72 h of AMI were identified and
compared with a matched control group (26). In-hospital
and follow-up mortality were not significantly different
between both groups. On multivariate analysis, however,
the time from presentation to occurrence of nonsustained
VT was a predictor of subsequent mortality, with the
highest risk for patients who had the arrhythmia approxi-
mately 24 h after AMI. The present study did not evaluate
the prognostic value of nonsustained VT within the first
72 h of AMI, but rather that of VT runs documented 10 6
6 days thereafter. Studies in the prethrombolytic era, on the
other hand, found the highest prevalence of nonsustained
VT one month after AMI (27). Thus, there seems to be
some uncertainty as to the most appropriate time point at
which Holter recordings should be assessed for optimization
of the predictive value of nonsustained VT.
Clinical implications. Given the high efficacy of the ICD
in preventing arrhythmogenic death (28), there appears to
be the need of further primary prevention trials, particularly
in postinfarction patients. Such trials will only be accepted
by the scientific community and by clinicians taking care of
infarct survivors if they demonstrate a reduction in all-cause
mortality (29). This requirement makes risk stratification
particularly demanding in this patient population. From the
results of this as well as from other studies, it seems that the
use of spontaneous nonsustained VT documented at the
time of hospital discharge is of limited value. Only very few
patients after AMI demonstrate both nonsustained VT and
depressed LVEF. Thus, the criteria applied to the MADIT
population (7) are only rarely observed shortly after AMI. It
remains to be demonstrated, however, that other risk
stratifiers may yield clinical benefit in this respect. For
instance, the predictive value of the combination of de-
pressed left ventricular function and impaired heart rate
variability is currently being examined in a large interventional
study (30). Only such prospective intervention trials will be
able to answer these clinically important questions (29).
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